From e535a86a288a5770c0c3f901364d906c7008c8ea Mon Sep 17 00:00:00 2001 From: m3taversal Date: Wed, 18 Mar 2026 14:52:02 +0000 Subject: [PATCH] =?UTF-8?q?leo:=20resolve=20merge=20conflict=20=E2=80=94?= =?UTF-8?q?=20apply=20Aon=20GLP-1=20enrichments=20to=20post-restructure=20?= =?UTF-8?q?main?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit - What: Cherry-picked Aon employer cost savings enrichments, resolved conflicts with WHO GLP-1 enrichments (both kept) - Why: Epimetheus archive restructure + parallel WHO enrichment merge caused conflicts Pentagon-Agent: Leo --- ...t cost impact inflationary through 2035.md | 5 +++ ...ients-undermining-chronic-use-economics.md | 5 +++ ...just-clinical-factors-drive-persistence.md | 6 ++++ ...eating-largest-per-patient-cost-savings.md | 6 ++++ ...mployer-cost-savings-cancer-reduction.json | 32 +++++++++++++++++++ ...-employer-cost-savings-cancer-reduction.md | 15 ++++++++- 6 files changed, 68 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index bf3d05709..7bb332dc9 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -89,6 +89,11 @@ BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plu WHO's conditional recommendation structure and behavioral therapy requirement suggest the 'chronic use model' framing may be incomplete. The guideline establishes medication-plus-behavioral-therapy as the standard, not medication alone, which may have different economics than the pure pharmaceutical model. WHO also announced it will develop 'an evidence-based prioritization framework to identify which adults with obesity should be prioritized for GLP-1 treatment'—implying targeted use rather than universal chronic treatment. +### Additional Evidence (challenge) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18* + +Aon's 192K patient analysis shows medical costs grow only 2% for GLP-1 users after 12 months versus 6% for non-users, with diabetes patients showing 6-9 percentage points lower cost growth at 30 months depending on adherence. This suggests the 'inflationary through 2035' claim may be payment-model-dependent rather than universally true—capitated long-term risk-bearers may see net savings while FFS short-term payers see inflation. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 40852332c..91d290727 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -77,6 +77,11 @@ BALANCE Model's manufacturer-funded lifestyle support requirement directly addre WHO's conditional recommendation requiring behavioral therapy combination provides international regulatory support for adherence interventions. The guideline explicitly states GLP-1s should be 'combined with intensive behavioral therapy to maximize and sustain benefits'—directly addressing the persistence problem by making behavioral support the standard of care rather than an optional add-on. +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18* + +Aon data shows adherence is the binding variable for cost-effectiveness: the 80%+ adherent cohort shows 9 percentage points lower cost growth for diabetes and 7 points lower for weight loss, versus 6 and 3 points for the overall population. This means the economic case requires not just persistence but high adherence, making the 15% two-year persistence rate even more problematic for chronic use economics. + --- Relevant Notes: diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index b9259e3a0..0b25f3758 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -43,6 +43,12 @@ The source does not provide granular income-stratified discontinuation rates, so The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations. + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18* + +Aon data shows the 80%+ adherent cohort captures dramatically stronger cost offsets (9 points for diabetes vs 6 for overall population), meaning affordability barriers that reduce adherence don't just affect clinical outcomes—they eliminate the economic case for coverage, creating a self-reinforcing cycle where cost concerns prevent the adherence needed to justify the cost. + --- Relevant Notes: diff --git a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md index 278f2b9b6..9fbe0250a 100644 --- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md +++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md @@ -40,6 +40,12 @@ FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major k SELECT trial economic model shows $2,074 per-subject lifetime savings from avoided CKD, supporting the claim that kidney protection generates substantial cost savings. However, diabetes prevention ($14,431) generates even larger savings. + +### Additional Evidence (confirm) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18* + +Aon's real-world claims data confirms the temporal pattern of GLP-1 cost offsets: medical cost growth is 6 percentage points lower at 30 months for diabetes patients, with the savings materializing after the first 12 months when costs initially rise 23% versus 10% for non-users. This validates the kidney protection findings in a large commercial population. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json b/inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json new file mode 100644 index 000000000..c65d126b6 --- /dev/null +++ b/inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-18", + "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:set_created:2026-03-18" + ], + "rejections": [ + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor", + "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-18" +} \ No newline at end of file diff --git a/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md b/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md index 0caf70348..b4a8aff83 100644 --- a/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md +++ b/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md @@ -7,9 +7,13 @@ date: 2026-01-13 domain: health secondary_domains: [internet-finance] format: report -status: unprocessed +status: enrichment priority: high tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence] +processed_by: vida +processed_date: 2026-03-18 +enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -49,3 +53,12 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary. flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"] + + +## Key Facts +- Aon analyzed 192,000+ GLP-1 users in U.S. commercial health claims data +- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs 10% for non-users +- After 12 months: medical costs grow 2% vs 6% for non-users +- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence +- Adherent users (80%+): 47% MACE reduction for women, 26% for men +- Study released January 13, 2026